← The Wire·Regulation·

Cellebrite cuts guidance as CEO departs; fiscal 2025 revenue rose 18.6% to $475.7M

Cellebrite is navigating a CEO transition and guidance cuts alongside reported gains in AI and FedRAMP. The setup puts execution risk against a business that still posted fiscal 2025 revenue growth and high gross margins.

STOCK PHOTO · TIGER LILY

The story

Cellebrite faces a mixed outlook with leadership changes and guidance reductions offset by progress in artificial intelligence and FedRAMP compliance capabilities. Fiscal 2025 revenue reached $475.7M, up 18.6% year over year, with an 84.2% gross margin, a 16.5% net margin and $0.31 of diluted EPS, establishing a profitable, growing base. However, the magnitude of the guidance cuts remains unclear, as does the full impact of the CEO transition on strategic direction. The critical question is whether the newer AI and FedRAMP product wins will translate into sufficient contracted revenue growth to offset near-term execution concerns. Management's detailed explanation of the leadership change and quantifiable evidence of how AI and FedRAMP are contributing to the business pipeline will be essential to assessing the company's true earnings trajectory.

Our read · Fri, Aug 21

The CEO transition and guidance cuts move execution risk higher for CLBT, while its 18.6% revenue growth and 84.2% gross margin keep the long-term operating case intact.

Why. The immediate read is mixed: leadership turnover and lower guidance raise uncertainty, but the fiscal 2025 profile shows a profitable business with $475.7M of revenue, 18.6% year-over-year growth and an 84.2% gross margin. The missing guidance figures and unquantified AI and FedRAMP contribution prevent a defensible single-name directional trade.

Both cases

The case it holdsCLBT’s fiscal 2025 revenue grew 18.6% year over year with an 84.2% gross margin and 16.5% net margin, while AI and FedRAMP gains could support continued demand.
The case it breaksThe guidance cuts and CEO shift represent concrete execution warnings that raise questions about management confidence in near-term results, while the offset from AI and FedRAMP gains remains unquantified and uncertain.

What could change this view: A larger-than-signaled guidance reduction or evidence that the CEO change reflects deeper execution problems would weaken the operating case; conversely, quantified AI and FedRAMP bookings could remove the current uncertainty.

Cellebrite DI stock page →
Your side is graded privately against closes after 10 trading days. Research, not advice.

Who reported it · 1

Keep reading

Latest on the Wire

Fed releases October meeting minutes three weeks after policy decisionAnthropic Said to Guide IPO Pricing Above Market RangeXi gives Trump a rare hug at Shenzhen airport as US-China tone softensLagarde says she will leave ECB early to counter election misinformationRansomware group The Gentlemen reportedly lists Nvidia for a leakContinue on the Wire →

Top this week

Nvidia allies lobby board to bring back Jensen Huang as CEONvidia chair rules out Huang return as CEO after 75% sales outlookNvidia interim CEO Colette Kress faces first earnings test after HuangNvidia CEO Jensen Huang reportedly resigns as US-China tensions riseNvidia CFO Colette Kress to serve as interim CEO after Jensen Huang
The Wire at 7 AM ET, free. Top stories with a bull and a bear case on each, every morning. No account needed.

About this report

Reported by Yahoo Finance as Cellebrite (CLBT): CEO Shift and Guidance Cuts Contrast With Surging AI and FedRAMP Gains, . Who answers for this

The only report in this record. Closes are licensed end-of-day data from Databento; the move after a story is its first close against the close before it. How this is decided →

Kept as written · your side, if you take one, is graded privately against licensed closes after 10 trading days · nothing here is advice · How the Wire is made →